Related Experiment Video
Updated: May 16, 2026
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Study on the anti-lung cancer effects of Gracillin from Reineckia carnea by targeting STC1
Aiping Cui1,2, Yihe Tian1,2, Hao Chen3
1The Clinical Medicine Research Center of the First Clinical Medical College, Gannan Medical University, Ganzhou, China.
Background:
Gracillin, a steroidal saponin isolated from Reineckia carnea, exhibits broad anti-tumor activity. However, current studies on its mechanisms of action against lung cancer remain scarce, necessitating further investigation to elucidate the specific targets of its anti-tumor activity. This study aims to preliminarily elucidate the effects of Gracillin against human non-small cell lung cancer (NSCLC) cells and its potential mechanisms.
Methods:
NCI-H1299 cells were selected for in vitro cell experiments. Gracillin's cytotoxic, pro-apoptotic and anti-metastatic effects were assessed by CCK-8, flow cytometry, wound healing, Transwell assays and Western Blot. Potential target STC1 was identified through RNA-sequencing and validated via RT-qPCR, ELISA, and immunofluorescence. Interaction between Gracillin and STC1 was confirmed by molecular docking and SPR. STC1 knockdown and pathway inhibitors were applied to explore the role of STC1 and MAPK/ERK signaling in Gracillin's actions.
Results:
Gracillin inhibited proliferation, migration, invasion and induced apoptosis in NCI-H1299 cells. RNA-sequencing and validation assays identified that STC1's expression and secretion were upregulated by Gracillin. Direct binding between Gracillin and STC1 was confirmed by the values of molecular docking and SPR. Then, knockdown of STC1 attenuated Gracillin's anti-tumor effects and suppressed its activation of the ERK pathway. Furthermore, the inhibition of ERK pathway reversed Gracillin-mediated suppression of proliferation, migration and invasion.
Conclusions:
Gracillin exerts its inhibitory effects on the proliferation, migration, and invasion of NCI-H1299 cells by targeting STC1 protein, upregulating STC1 protein level, and subsequently activating the ERK signaling pathway. Gracillin holds promise as a targeted therapeutic agent for NSCLC.
Insights
Gracillin, a natural compound, inhibits non-small cell lung cancer (NSCLC) by targeting STC1 and activating the ERK pathway. This research highlights Gracillin
Area of Science:
- Pharmacology and Molecular Biology
- Cancer Research
- Natural Product Chemistry
Background:
- Gracillin, a steroidal saponin from Reineckia carnea, shows broad anti-tumor activity.
- Limited research exists on Gracillin's mechanisms against lung cancer.
- Understanding Gracillin's targets is crucial for its therapeutic potential in NSCLC.
Purpose of the Study:
- To investigate Gracillin's effects on human non-small cell lung cancer (NSCLC) cells.
- To elucidate the molecular mechanisms underlying Gracillin's anti-cancer activity.
- To identify and validate potential molecular targets of Gracillin in NSCLC.
Main Methods:
- In vitro experiments using NCI-H1299 NSCLC cells.
- Assessment of cytotoxic, pro-apoptotic, and anti-metastatic effects via CCK-8, flow cytometry, wound healing, and Transwell assays.
- Identification and validation of STC1 as a target using RNA-sequencing, RT-qPCR, ELISA, immunofluorescence, molecular docking, and SPR; STC1 knockdown and pathway inhibitors were employed.
Main Results:
- Gracillin significantly inhibited NSCLC cell proliferation, migration, invasion, and induced apoptosis.
- Gracillin upregulated STC1 expression and secretion, with direct binding confirmed.
- STC1 knockdown attenuated Gracillin's anti-tumor effects and ERK pathway activation; ERK inhibition reversed Gracillin's effects.
Conclusions:
- Gracillin inhibits NSCLC proliferation, migration, and invasion by targeting STC1 and activating the ERK signaling pathway.
- Upregulation of STC1 protein levels is a key mechanism in Gracillin's anti-cancer action.
- Gracillin demonstrates potential as a targeted therapeutic agent for NSCLC.